Nothing Special   »   [go: up one dir, main page]

ATE359076T1 - Mittel gegen juckreiz - Google Patents

Mittel gegen juckreiz

Info

Publication number
ATE359076T1
ATE359076T1 AT97912539T AT97912539T ATE359076T1 AT E359076 T1 ATE359076 T1 AT E359076T1 AT 97912539 T AT97912539 T AT 97912539T AT 97912539 T AT97912539 T AT 97912539T AT E359076 T1 ATE359076 T1 AT E359076T1
Authority
AT
Austria
Prior art keywords
remedies
itching
morphinian
antipruritic
opiate
Prior art date
Application number
AT97912539T
Other languages
English (en)
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Junzo Kamei
Kuniaki Kawamura
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE359076(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE359076T1 publication Critical patent/ATE359076T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Magnetic Record Carriers (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Elimination Of Static Electricity (AREA)
  • Table Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Non-Alcoholic Beverages (AREA)
AT97912539T 1996-11-25 1997-11-21 Mittel gegen juckreiz ATE359076T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25

Publications (1)

Publication Number Publication Date
ATE359076T1 true ATE359076T1 (de) 2007-05-15

Family

ID=18041771

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03001740T ATE263563T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT97912539T ATE359076T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03001740T ATE263563T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03001739T ATE291429T1 (de) 1996-11-25 1997-11-21 Mittel gegen juckreiz

Country Status (15)

Country Link
US (2) US6174891B1 (de)
EP (5) EP1327444B1 (de)
KR (1) KR100557801B1 (de)
CN (3) CN1535687A (de)
AT (3) ATE263563T1 (de)
AU (1) AU738743B2 (de)
CA (1) CA2244256C (de)
DE (3) DE69732868T2 (de)
DK (1) DK0897726T3 (de)
ES (3) ES2236630T3 (de)
NO (1) NO316309B1 (de)
NZ (1) NZ331001A (de)
PT (1) PT897726E (de)
TW (1) TW542838B (de)
WO (1) WO1998023290A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
ATE384532T1 (de) * 1996-12-24 2008-02-15 Elkhoury George F Topische anwendung von opioiden, wie morphin, zur linderung von juckreiz und hautkrankheiten sowie hautreizungen
WO1999003459A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif
WO2001014383A1 (fr) * 1999-08-24 2001-03-01 Toray Industries, Inc. Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques
WO2001074819A1 (fr) * 2000-04-03 2001-10-11 Toray Industries, Inc. Agents analgesiques contenant des derives de n-oxyde de morphinane en tant que principe actif
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
ES2319265T3 (es) * 2001-03-30 2009-05-06 Toray Industries, Inc. Farmacos para el sindrome de piernas inquietas.
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
JP4239592B2 (ja) * 2001-05-08 2009-03-18 東レ株式会社 敗血症治療剤
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
CA2464528A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
ES2390052T3 (es) 2002-03-29 2012-11-06 Santen Pharmaceutical Co., Ltd. Agonistas del receptor opioide kappa que comprende un derivado de 2-fenilbenzotiazolina
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
PT1543010E (pt) * 2002-09-25 2007-07-26 Euro Celtique Sa Hidromorfonas n-substituídas e a sua utilização
CA2561509C (en) 2004-03-30 2012-08-28 Toray Industries, Inc. Anti-itching agent
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
CN101137658B (zh) * 2005-03-10 2011-06-08 东丽株式会社 用于与多发性硬化症伴随的搔痒的止痒剂
RU2397173C2 (ru) 2005-04-06 2010-08-20 Торей Индастриз, Инк. Кристаллические производные морфинана и способ их получения
TW200806294A (en) * 2005-11-09 2008-02-01 Toray Industries Therapeutic or prophylactic agent for functional intestinal injury
AU2006328765B2 (en) * 2005-12-21 2012-01-12 Toray Industries, Inc. Antitussive agent
AU2007297827B2 (en) * 2006-09-20 2012-09-20 Mallinckrodt Llc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
CA2680205C (en) * 2007-03-06 2015-06-30 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2008133297A1 (ja) 2007-04-24 2008-11-06 Toray Industries, Inc. ジスキネジアの治療または予防剤
JP5099127B2 (ja) * 2007-04-26 2012-12-12 東レ株式会社 4,5−エポキシモルヒナン誘導体を含有する安定な固形製剤
US8183256B2 (en) * 2007-06-22 2012-05-22 Toray Industries, Inc. Remedy or preventive for integration dysfunction syndrome
RU2440117C1 (ru) * 2007-10-05 2012-01-20 Торэй Индастриз, Инк. Терапевтическое средство для улучшения свойств кожи, включающее в качестве действующего ингредиента производное морфинана или любую из его фармакологически приемлемых кислотно-аддитивных солей
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
JP6027315B2 (ja) * 2008-05-27 2016-11-16 マリンクロッド エルエルシー ノルモルフィナンの調製のための方法および化合物
US9458109B2 (en) 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
EP2398806A1 (de) * 2009-02-23 2011-12-28 Mallinckrodt LLC (+)-morphinanium-n-oxide und verfahren zu ihrer herstellung
CN102325775A (zh) * 2009-02-23 2012-01-18 马林克罗特公司 (+)-6-羟基-吗啡喃或(+)-6-氨基-吗啡喃衍生物
US8436174B2 (en) * 2009-02-23 2013-05-07 Mallinckrodt Llc (+)-morphinanium quaternary salts and processes for their production
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TWI477505B (zh) * 2010-01-29 2015-03-21 Toray Industries 膽管疾病之治療或預防劑
EP2671585B1 (de) 2011-01-31 2016-07-13 Toray Industries, Inc. (-)-17-(Cyclopropylmethyl)-3,14ß-Dihydroxy-4,5a-Epoxy-6ß-[N-Methyl-trans-3-(3-Furyl)acrylamido]Morphinan zur Verwendung bei der Behandlung oder Vorbeugung von Krebskachexie
JP2014526467A (ja) 2011-09-08 2014-10-06 マリンクロッド エルエルシー 中間体の単離なしでのアルカロイドの調製
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112015013984A2 (pt) * 2012-12-14 2017-07-11 Trevi Therapeutics Inc métodos para o tratamento de prurido
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2016052617A1 (ja) * 2014-09-30 2016-04-07 国立大学法人筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
ES2970294T3 (es) * 2016-03-21 2024-05-27 Trevi Therapeutics Inc Tratamiento del prurito urémico
CN108883185B (zh) * 2016-12-06 2021-10-08 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
US20210015813A1 (en) 2018-03-08 2021-01-21 Victoria Link Ltd. Treatment of demyelinating diseases
CN118477079A (zh) 2018-07-23 2024-08-13 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
AU2020250468A1 (en) * 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
WO2022004788A1 (ja) 2020-06-30 2022-01-06 東レ株式会社 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
EP0398720A3 (de) * 1989-05-18 1991-07-03 Glaxo Group Limited Piperazin-Derivate
ATE172201T1 (de) * 1992-01-23 1998-10-15 Toray Industries Morphinan-derivate und medizinische verwendung
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
DE69413933T2 (de) * 1993-06-30 1999-04-08 Toray Industries, Inc., Tokio/Tokyo Antitussiva
JPH09504018A (ja) * 1993-10-20 1997-04-22 ザ ブーツ カンパニー ピーエルシー 抗掻痒薬としてのイブプロフェンおよびフルルビプロフェン
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
WO1999003459A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
DE69737592D1 (de) 2007-05-24
DE69732868T2 (de) 2006-04-13
KR100557801B1 (ko) 2006-04-21
CN1214634A (zh) 1999-04-21
EP0897726B1 (de) 2007-04-11
CA2244256C (en) 2006-07-11
DE69728585D1 (de) 2004-05-13
EP1312361A1 (de) 2003-05-21
DK0897726T3 (da) 2007-08-13
CN1535687A (zh) 2004-10-13
CN1180844C (zh) 2004-12-22
US6316461B1 (en) 2001-11-13
KR19990081978A (ko) 1999-11-15
NZ331001A (en) 2000-05-26
ATE263563T1 (de) 2004-04-15
NO316309B1 (no) 2004-01-12
EP0897726A1 (de) 1999-02-24
DE69728585T2 (de) 2004-08-05
DE69737592T2 (de) 2008-01-03
TW542838B (en) 2003-07-21
US6174891B1 (en) 2001-01-16
EP1310255B1 (de) 2004-04-07
ATE291429T1 (de) 2005-04-15
ES2215158T3 (es) 2004-10-01
EP1327444B1 (de) 2005-03-23
EP1327444A1 (de) 2003-07-16
ES2285733T3 (es) 2007-11-16
JP3531170B2 (ja) 2004-05-24
ES2236630T3 (es) 2005-07-16
DE69732868D1 (de) 2005-04-28
NO983431L (no) 1998-09-24
PT897726E (pt) 2007-07-09
EP1310251A1 (de) 2003-05-14
CA2244256A1 (en) 1998-06-04
AU738743B2 (en) 2001-09-27
WO1998023290A1 (fr) 1998-06-04
CN1291717C (zh) 2006-12-27
EP0897726A4 (de) 2003-05-28
AU4968397A (en) 1998-06-22
NO983431D0 (no) 1998-07-24
EP1310255A1 (de) 2003-05-14
CN1530111A (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
ATE291429T1 (de) Mittel gegen juckreiz
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
ID18883A (id) Pesaing 5-ht 1f
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69928655D1 (de) Substituierte porphyrine
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
PT1117403E (pt) Antagonistas de mglurs para o tratamento da dor e ansiedade
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
EA199900912A1 (ru) Фармацевтические средства
BR9807883A (pt) Compostos de tetraidropirido
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
PT977716E (pt) Utilizacao de alcoois como aditivos para rebocos e/ou argamassas
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
IL139144A0 (en) Mycobacterial inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0897726

Country of ref document: EP